Public Release: 22-Dec-2014 Test predicts response to treatment for ...
(New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a ...
EurekAlert (press release) - Mon, 22 Dec 2014 15:34

Test Predicts Response to Early Treatment for Dangerous Complication of Stem ...
Newswise (press release) - Mon, 22 Dec 2014 15:37

RainDance Forms Hematologic Oncology Consortium to Develop Assays for ...
RainDance Technologies Inc. a genomics tools company simplifying the analysis of complex genetic diseases today announced the formation of the RainDance HemOnc Consortium composed of a select group of hematologic clinical research experts drawn ...
PharmiWeb.com (press release) - Fri, 05 Dec 2014 04:56



Lackluster T-DM1 Results Surprise Perez
Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with ...
OncLive - Mon, 22 Dec 2014 12:48



MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of ...
Pracinostat is an oral histone deacetylase (HDAC) inhibitor that has been tested in a number of Phase I and Phase II clinical trials in advanced hematologic disorders and solid tumor indications in both adult and pediatric patients. Pracinostat has ...
PR Newswire (press release) - Mon, 22 Dec 2014 06:03



Hematology Advances Take Center Stage at ASH
One that is expected to attract considerable interest is a session about new FDA-approved therapies for hematologic conditions. Lee said the session evolved from a perceived need among clinicians for information about some of the recent FDA approvals ...
MedPage Today - Fri, 05 Dec 2014 10:30

ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon
The Myeloma Beacon - Fri, 05 Dec 2014 07:49

BLAST: Blinatumomab may effectively combat minimal residual disease in ALL
All patients had B–precursor ALL in complete hematological remission. They received one cycle ff the study drug at 15 µg/m2 per day for 28 days per cycle. Complete minimal residual disease response served as the primary endpoint. Adverse events also ...
Healio - Fri, 19 Dec 2014 01:07



The Year in Hematologic Malignancies
The problem is that some of those changes, such as renal insufficiency and bone disease, can be debilitating once they occur," said Dr Kumar. "The new guidelines move the bar for treating a little lower. Now, if clinicians see bone marrow plasma cells ...
Medscape - Thu, 11 Dec 2014 11:15

Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE ...
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
Business Wire (press release) - Wed, 03 Dec 2014 04:00


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014